Tuvonralimab
Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2].
Product Specifications
CAS Number
[2417649-44-4]
Product Name Alternative
PSB-205; QL1706 (iparomlimab/tuvonralimab) ; PBS105
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tuvonralimab.html
Purity
99.14
Solubility
10 mM in DMSO
Smiles
[Tuvonralimab]
Molecular Weight
(145 kDa)
References & Citations
[1]Keam SJ. Iparomlimab and Tuvonralimab: First Approval. Drugs. 2025 May;85 (5) :699-706.|[2]Ian Wilkinson, et al. Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names. MAbs. 2022 Jan-Dec;14 (1) :2123299.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15133569 1 Vial
Lentiviral human N6AMT1 shRNA (UAS) - Lentiviral human N6AMT1 shRNA (UAS, GFP) (100)
Ask
View Details 128979-ML490 100 µL
L3MBTL4 (Lethal (3) malignant Brain Tumor-like Protein 4, H-l (3) mbt-like Protein 4, L (3) mbt-like Protein 4) (MaxLight 490)
Ask
View Details